【摘要】 研制了基因工程靶向融合蛋白XE-TNFαm2。其中,XE为HIV/SIV辅助受体CXCR4的第二胞外域;TNFαm2是经突变改型的TNFα,其毒副作用已降低18倍,己用于临床治疗恶性肿瘤。己有的研究表明XE-TNFαm2的功能之一是杀灭受HIV/SIV感染的细胞、但不杀伤未受HIV/SIV感染的正常细胞。探讨XE-TNFαm2可否引起细胞的凋亡,以阐明其杀伤细胞作用的可能机制。结果表明,XE-TNFαm2只能引起受HIV/SIV感染细胞的凋亡,但不能引起未受HIV/SIV感染的正常细胞的凋亡。这一结果表明XE-TNFαm2是一种可特异杀灭受HIV/SIV感染细胞的准确靶向融合蛋白,其毒副作用己最小化。更多还原

【Abstract】 Engineered targeting fusion protein XE-TNFαm2 was prepared.In which,XE is the second excellular domain of CXCR4,a co-receptor of HIV/SIV;TNFαm2 is a mutation protein of TNFα.Its side effect was reduced 18 fold.It has been used in clinic for cancer therapy.Our previous study indicated that one of XE-TNFαm2 functions is to kill the cells infected by HIV/SIV,but,not to kill the normal cells without HIV/SIV.The purpose in this study is that to explore whether XE-TNFαm2 could lead cell to apoptosis,as its effect mechanism.The result shows that XE-TNFαm2 only can lead the apoptosis of cells infected by SIV,but can not lead this effect on normal cells without HIV/SIV.It indicates that XE-TNFαm2 is an accurate targeting fusion protein to specifically kill cells infected by HIV/SIV,but not be able to kill normal cells without HIV/SIV.It side effect is minimized.更多还原